DOCSLIB.ORG

Of Authors' Names

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Of Authors' Names View Article Online / Journal Homepage / Table of Contents for this issue INDEX OF AUTHORS’ NAMES. ABSTRACTS. 1885. And also to Transactions, 1885 (marked TRANS.); and to such papers as appeared in Abstract of Proceedings but not in Transactions (marked PROC.). A. And6s, L. E., preparation of wood stains in the solid form, ’711. Abney, W.deW., andR.Festing,ab- Andouard, A., estimation of gum sorption spectra thermograms, 1175. arabic in syrup, 299. -- relation between energy and Andouard, d., and V. DQzauna;r, radiation in the spectrum of incan- mfiuence of exhausted beet root pulp descence lamps, 325. on cow’s milk, 73. Albertoni, K., action and metamor- An drae, desiccation of seed potatoes, phoses of Bome Substances in the 1155. organism in relation to diabetes, 683. And r 6, G., ammonio-cupric sulphate blbitzky, A., p-dipropylzcrylic wid, alid a basic cupric sulphate, 8’73. 242. - basic and ammoniacal nitrates, - refractive power of the hgdro- 634. carbon C12H20,211. -ammonio-zinc sulphates, 485. Aitken, A. P., report on ensilage and Andre. See Berthelot. manuring beans and barley, 1255. And reae, J. L., method for estimating Alekhine, A., anhydrides of mannitol, the specific gravity of solid substances 744. soluble in water, 332. Alexheff, P., action of light nitro- - specific gravity of saturated EO~U- cumic acid, 794. tions of solid substances at various -derivatives of azocumic acid, 390. temperatures, 334. AlexBeff, W., reciprocal solution of Andrews, T., electromotire force be- liquids, 340. tween metals at high temperatures, -stability of compounds, 114. 11’75. Allen, A. H., estimation of ethyl ni- Anrep, B. v., physiological actiou of trite in spirit of nitrous ether, &c., ptomai’nes, 682. 1013. Anschiitz, R., action of phosphoric Allen, A. W. See Norton. chloride on salicylic acid, 1061. Published on 01 January 1885. Downloaded by Ryerson Polytechnic University 09/08/2013 00:18:45. Allen, W., and A. Kolliker, deriva- -- formation of the anhydrides of tives of triphenylcarbinyl bromide, 655. mono- and di-basic acids, 243. Allihn, F., apparatus for filtering in a -formation of meth.) 1racemate from vacuum, 631. methyl dextro- and lee-c.o-tartrates, Amagat, E. H., correctionof the results 966. given in a paper on compressed gas -malic acids, 1049. manometers, 341. - new method of preparing aromatic - density and atomic volumes of hydrocarbons, 1064, and TRANS.,898. oxygen and hFdrogen, 631. -pipitzahoic acid, 776. Am t 11 or, C., caramel, 604. -racemic acid, and the calcium salts -niiclein of grape stones, 823. of the four tartaric acids, 243. Ancel. See Bauer. -replacement of two chlorine atoms A n d e e r, J., phlorglucinol as an anti- in chlorides by means of anhydrous septic, 454. oxalic acid, 263. VOL. PLVLII. 4 1‘ View Article Online 1278 INDEX OF QUTHORS. Anschutz, R., and C. Hintze, di- Aubert, L., and V. Girard, manufac- ammonium oxalate, 1049. ture of cane-sugar from starch, 1274. Anschiitz, R., and H. Immendorff, Aubert, P. See LQpine. action of aluminium chloride, 269. Aubin, E., estimation of phosphoric --preparation of homologues of acid, 1093. benzene by aid of aluminium chloride, Au bin. See also Nuntz. 769. Au douar d, analysis of phosphatic Anschiitz, R., and A. Eeku16, useful manures, 838. apparatus, 1035. Audopnaud, A., and E. Zachare- Anschiitz, R., and F. Klingemann, wicz, farmyard manure, 834, 1260. preparabion of malic acid from citric dusten, P. T., and F. A. Wilber, acid, 1050. purification of drinking water by alum, Anschiitz, R., and W. Leather, de- 936. rivatives of pipitzahoic acid, 777. Auwera, K., pseudocumenol, 380. Anschiitz, R., and P. Meyer, amido- and hydroxy - phenanthraquinones, 1067. B. Anschutz and E. Romig, action of aluminium chloride on mixtures of B aey er, A., polyacetylene compounds, ethylidine chloride with benzene, 759, 1198. toluene, or’metaxylene, 768. Baginsky, A., occurrence of xanthine, -- nitration products of di- guanine, and hypoxanthine, 286. phenylethane, 800. - use of milk preserved by high Anschiitz, R., and &. Wirtz, decom- temperatures for children’s food, 679. position of ayomatic salts of fumaric Baker, H., orthovanadates of aodiuxu, acid, 1064, and TRAYS.,899. &c., TBANS.,353. Ant ric k, O., benzylindole, 543. Baker, H. B., combustion in dried -compounds of diacetoiiamine with gases, TRANS.,349. aldehydes, 502. Bakker, R. P., tengkawang fat or Antrick. See also Enorr. vegetable tallow, 710. Archbutt, L., free acid in oils, 446. B a1b i an o, L., derivatives of bromanisic Arche, A., and C. Hassack, analpis acid, 530. of some Indian bronzes and their Balmer, J. E., spectrum lines of hy- patina, 100. drogen, 1025. Aristoff, V., oxidation of acids of the Barnberger, E., colour reactions of lactic Reries, 752. orthodiLetones, PO?. Armstrong, El. E,, constitution of -mixed azo-compounds, 157. the fulminates, TRANS.,79. -retene, 549. Armst,rong, H. E., and A. K. Miller, Bamberger, E., and 5. C. Hooker, products of the manufacture of gas retene, 905. from petroleum, PROC.,77. --conatitubion of retene, 1070. Published on 01 January 1885. Downloaded by Ryerson Polytechnic University 09/08/2013 00:18:45. Ariiaud, M., colouring ma%ter of Bamberger, E., and J. Kranzfeld, leaves, 670. chrysene, 1069. Arnold, C., estimation of chlorides in Barbsglia; G. A., parabuninidine, a urine, 835. fourth alkalo’id from Buxus semper- -estimation of nitrogen, 837. virelzs, 177. - Kjeldahl’s method of nitrogen -thiovaleraldehyde, 136. estimation, 930. Barbier, E., relation between the Arons, L., heat of dilution and Rpeeific ordinary thermometer and the weight heat of saline solutions, 1101. thermometer, 111. Arth, G., action of anhydrous am- Barbieri. See Sachs. moniacal ammonium nitrate on metals, Barker, G-. F., and others, report on 1039. glucose, 206. Arzruni, A., groddeckite, a new zeo- Barnes, J., sepamtion of metals Dre- lite, 32. cipitated by hydrochloric acid, 59?. -minerals from a chromite deposib, Barroiq chloritoyd from Morbihan, 31. 1118. -sulphur from Zielenzig, 27. Bart h, M., abnormal fermentation Ata n a s e s c 0, analysie of artificial under unfavourable circumstances, brochantite, 1117. 942. Atwater, W. O., acquisition of atmo- -specific influence of acetic acid on spheric nitrogen by plants, 1005. the fermentation of must, 942. View Article Online IXDEX OF AUTHORS. 1279 Ba.rth, J., and 1,. Schreder, suh- Bechi, detection of cotton seed oil in stances formed by the fusion of quinol olive oil, 301. with soda, 520. Beckenkamp, J., the coe5cients of Bartoli, A., capillary constants of elasticity of crystals, 729. liquids and cohesion of solids, 866. Bec ker, F., aluminium sulphate, 1271. -conductivity of cetyl alcohol, 855. -estimation of tannin, 934. -electrical conductivity of carbon Beckurts, H‘, estimation of arsenic in compounds, 624. judicial cases, 439. -impermeability of glass togases, 869. -hydrochloric acid in Marsh’s appa- -relation between fusing and boiling ratus, 440 points, 859. -preparation of hydrochloric acid Bartoli, A., and E. Stracciati, free from arsenic, 4M. critical volumes of paraffins, 859, -separation of alkaloids in, forensic --MendelCeff’s formula for the analpis, 701. expansion of liquids, 859. -strychnine, 675. Bar z ilov s k y, J.,oxidation of aromatic -strrchnine and brucine, 911. diamines, 525. Beckuits, H,, and R. Otto, action of Battut, L., estimation of sugars and heat and water on the halogen sub- glucoses, 693. stituted acids of the C,H2,O2 series, -sulphurous anhydride in sugar 506. refining, 709. -monohalogen-derivatives of aerylic Bauer, H., boiling point anomalies of acid, 509. the chlorinated acetonitriles and their Beckurts. See also Otto. derivatives, 1120. Becqucrel, E., spectroscopic study of Bauer, M., 2. Rrouard, and J. compounds rendered pliosphoresc~nt A nc el, vegetable leather, 851. by the action of light on electrical B a u e r, It., azobenzenethiosulphonic discharge, 109b. acid : azobenzenesulphonic acid, 1139. B e e t z, W. v., constant element for I) a u e r, R. W., sugar from Agar-Agar, electrical measurements, 2. 500. BQhal, A., separation of copper and B aum, J., simple method for preparing cadmium, 1012. hippuric acid and allied compounds, Behrend, P., chasgee occwring in 981. barley during malting, 617. Baum. See also Schotten. B e h re n d, R., derivatives of carbamide, Baumann, E., compounds of mercap- 246. tans with aldehydes, ketones, and Behrmann, A., and A.W. Hofmann. ketonic acids, 748. amides of citric acid and their comer- -derivatives of pyruvic acid, 513. sion into pyridene-derivatives, 138. Baumann. See also Nolting. Beilby, G., preparation of ammonia B aumert, G.,lupinidine from Lupinus from nitrogenous minerals. 304. luteus, 177. Beilstein, F., and E. IYiioganil, Published on 01 January 1885. Downloaded by Ryerson Polytechnic University 09/08/2013 00:18:45. -behariour of lupinidine with ethyl angelic and tiglic acids, 42. iodide, 676. -- unsaturated compounds of Baumhauer, E. H. v., simple form of the fatty series 740. thermo-regulator and registering ther- Bell, L., absorption spectrum of nitro- mometer, 471. gen peroxide, 949. -- the Ngawi meteorite, 1190. - spectroscopic determination of Eaumstark, E”., new methodof proxi- lithium, 1012. mate resolution of the brain sub- Bellamy, F., action3of some metala on stance, 918. mixtures of acetylene and air, 951. B B cham p, A., optical inactivity of Belohoubek, A., colouring matters cellulose, 500. from ebony wood, 396. -optical inactivity of celluIose and BQmont. See Ekard. the rotary power of pyroxylin, 237. Benas, T., naw tin salts, ’727. -organisms which produce zymases, -volumetrio estimation of tin, 839. 580. B enckiser. See Nietzki. -origin of microzymee and vibrioles, Bender, C., saline solutions, 12. 417. Benedikt, R., and C. Hazura, morin, -rotary power of solutions of 563. cellulose in Schweizer’s reagent, 369. Benedikt, R., and P. Jnlius, a nm Bkchamp, J., and A. Dujardin,the resorcinol blue, 386. zymase of jequirity, 1086. B enedikt. See also Weselsky. 4r2 View Article Online 1280 INDEX OF AUTHORS. Benoist. See Collin. Berthelot and Werner, heats of for- B e r an, A., paramidoctylbenzene, par- mation and transformation of the by- amidocaprylbenzene, and amidoctyl- droxybenzoic acids, 1103.
Load more

Recommended publications
  • Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease
    Pediatric Pulmonology 42:989–1001 (2007) State of the Art Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease. A Review of the Literature 1 1 1,2 Ruben Boogaard, MD, * Johan C. de Jongste, MD, PhD, and Peter J.F.M. Merkus, MD, PhD Summary. Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children. Pediatr Pulmonol. 2007; 42:989–1001. ß 2007 Wiley-Liss, Inc. Key words: mucolytic; sulfhydryl compounds; N-acetylcysteine; dornase alfa; hyper- tonic saline; respiratory tract disease. INTRODUCTION One possible means to evaluate a mucoactive agent is to assess its effect on mucociliary clearance (MCC) or cough Mucus clearance is an important primary innate airway clearance with the use of radiolabeled aerosol. Discussing defense mechanism, and our understanding of the key this subject is outside the scope of this review. Moreover, parameters underlying its function has grown rapidly in the studies on mucoactive agents in CF patients, and studies last decade.1,2 Impaired mucus clearance or mucus hyper- on physiotherapy or secretion clearance techniques in secretion are important clinical features in diseases such as (pediatric) lung disease patients have been reviewed by cystic fibrosis (CF), recurrent bronchitis, asthma, and others, and will therefore not be discussed in this review.
    [Show full text]
  • Supportive Care Medications
    th Clinical Pharmacy Guide: Cancer Drug Treatment Assessment and Review 5 Edition Supportive Care Medications Contents Introduction ................................................................................................................. 2 Supportive Care Information in Protocols .................................................................... 2 Antidiarrheals .............................................................................................................. 5 Loperamide ............................................................................................................. 5 Antiemetics .................................................................................................................. 6 Emetogenicity .......................................................................................................... 7 Types of Chemotherapy-Induced Nausea and Vomiting .......................................... 7 Classifications of Antiemetics .................................................................................. 8 Anti-infective Agents .................................................................................................. 10 Antibiotics .............................................................................................................. 10 Antivirals ................................................................................................................ 11 Arthralgias/Myalgias .................................................................................................
    [Show full text]
  • Table III: 2019 Medicare Drug Fee Schedule* CY 2019 4Th Quarter
    Table III: 2019 Medicare Drug Fee Schedule* CY 2019 4th Quarter Average Sales Price (ASP) Data Plus 6 Percent *The Medicare payments allowance limits are effective Oct. 1 through Dec. 31, 2019. CY 2019 CY 2019 CY 2019 CY 2019 Effective Jan. 1 Effective Apr. 1 Effective July 1 Effective Oct. 1 Through Mar. 31 Through June 30 Throught Sept. 30 Through Dec. 31 Code Description Code Dosage ASP plus 6 percent ASP Plus 6 percent ASP Plus 6 percent ASP plus 6 percent J0129 Abatacept 10mg $51.61 $52.49 $53.94 $54.32 J0130 Abciximab injection 10mg $1,429.07 $1,429.07 $1,429.07 $1,429.07 J0133 Acyclovir, 5 mg 5mg $0.05 $0.05 $0.04 $0.04 J0171 Adrenalin epinephrin inject 0.1mg $0.74 $0.76 $0.86 $0.83 J0207 Amifostine 500mg $979.75 $990.39 $977.31 $1,003.59 J0256 Alpha 1 proteinase inhibitor 10mg $4.55 $4.56 $4.51 $4.55 J0280 Aminophyllin 250 MG inj 250mg $7.02 $7.33 $7.33 $10.88 J0289 Amphotericin b liposome inj 10mg $22.19 $23.92 $18.32 $26.09 J0295 Ampicillin sodium per 1.5 gm 1.5gm $2.62 $2.81 $3.32 $2.06 J0360 Hydralazine hcl injection 20mg $2.58 $2.58 $4.07 $4.21 J0456 Azithromycin 500mg $2.76 $2.58 $2.75 $3.05 J0461 Atropine sulfate injection 0.01mg $0.07 $0.07 $0.07 $0.06 J0475 Baclofen 10 MG injection 10mg $169.75 $174.19 $173.39 $169.51 J0476 Baclofen intrathecal trial 50mcg $44.35 $49.98 $50.44 $50.05 J0480 Basiliximab 20mg $3,677.61 $3,687.17 $3,789.63 $3,799.93 J0490 Belimumab 10mg $44.16 $44.16 $44.82 $44.82 J0500 Dicyclomine injection 20mg $69.65 $82.33 $69.97 $57.58 J0515 Inj benztropine mesylate 1mg $18.67 $18.75 $19.89 $17.74 J0570
    [Show full text]
  • Mucoactive Agents for Airway Mucus Hypersecretory Diseases
    Mucoactive Agents for Airway Mucus Hypersecretory Diseases Duncan F Rogers PhD FIBiol Introduction Sputum Profile of Airway Inflammation and Mucus Hypersecretory Phenotype in Asthma, COPD, and CF Which Aspect of Airway Mucus Hypersecretion to Target? Theoretical Requirements for Effective Therapy of Airway Mucus Hypersecretion Current Recommendations for Clinical Use of Mucolytic Drugs Mucoactive Drugs N-Acetylcysteine: How Does it Work? Does it Work? Dornase Alfa Hypertonic Saline Surfactant Analysis Summary Airway mucus hypersecretion is a feature of a number of severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). However, each disease has a different airway inflammatory response, with consequent, and presumably linked, mucus hypersecretory phenotype. Thus, it is possible that optimal treatment of the mucus hyper- secretory element of each disease should be disease-specific. Nevertheless, mucoactive drugs are a longstanding and popular therapeutic option, and numerous compounds (eg, N-acetylcysteine, erdosteine, and ambroxol) are available for clinical use worldwide. However, rational recommen- dation of these drugs in guidelines for management of asthma, COPD, or CF has been hampered by lack of information from well-designed clinical trials. In addition, the mechanism of action of most of these drugs is unknown. Consequently, although it is possible to categorize them according to putative mechanisms of action, as expectorants (aid and/or induce cough), mucolytics (thin
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Mesna Injection
    AF 35421 Format 131401 #037B Size: 8.0” x 10.0” (Flat) 1.0” x 5.0” (Folded) PMS Black 03/20/13 Head to Head MSN-P01 Controlled Studies MESNA INJECTION FUKUOKA** 31%(14/46) 6% (3/46) Rx ONLY SCHEEF** 100% (7/7) 0% (0/8) *Ifosafamide dose 1.2 g/m2 d x 5 DESCRIPTION **Ifosfamide dose 2 to 4 g/m2 d x 3 to 5 Mesna Injection is a detoxifying agent to inhibit the hemorrhagic cystitis induced by ifosfamide. The active ingredient mesna is a synthetic INDICATIONS AND USAGE sulfhydryl compound designated as sodium-2-mercaptoethane sulfonate with a molecular formula of C H NaO S and a molecular weight 2 5 3 2 Mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. of 164.18. Its structural formula is as follows: – + CONTRAINDICATIONS HS-CH2-CH2SO3 Na Mesna is contraindicated in patients known to be hypersensitive to mesna or other thiol compounds. Mesna Injection is a sterile, nonpyrogenic, aqueous solution of clear and colorless to light pink appearance in clear glass multidose vials WARNINGS for intravenous administration. Mesna Injection contains 100 mg/mL mesna, 0.25 mg/mL edetate disodium and sodium hydroxide and/ or hydrochloric acid for pH adjustment. Mesna Injection multidose vials also contain 10.4 mg of benzyl alcohol as a preservative. The Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with solution has a pH range of 6.5 to 7.3. autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions.
    [Show full text]
  • Mesna: Drug Information
    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Mesna: Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Mesna: Patient drug information" and see "Mesna: Pediatric drug information") For abbreviations and symbols that may be used in Lexicomp (show table) Brand Names: US Mesnex Brand Names: Canada Mesna for injection; Uromitexan Pharmacologic Category Antidote; Chemoprotective Agent Dosing: Adult Note: Mesna dosing schedule should be repeated each day ifosfamide is received. If ifosfamide dose is adjusted (decreased or increased), the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio. Prevention of ifosfamide-induced hemorrhagic cystitis: Standard-dose ifosfamide (manufacturer’s labeling): IV: Mesna dose is equal to 20% of the ifosfamide dose given for 3 doses: With the ifosfamide dose, hour 4, and at hour 8 after the ifosfamide dose (total daily mesna dose is 60% of the ifosfamide dose) Oral mesna (following IV mesna; for ifosfamide doses ≤2 g/m2/day): Mesna dose (IV) is equal to 20% of the ifosfamide dose at hour 0, followed by mesna dose (orally) equal to 40% of the ifosfamide dose given 2 and 6 hours after the ifosfamide dose (total daily mesna dose is 100% of the ifosfamide dose). Note: If the oral mesna dose is vomited within 2 hours of administration, repeat the dose or administer IV mesna. Short infusion standard-dose ifosfamide (<2.5 g/m2/day): ASCO guidelines: IV: Total mesna dose is equal to 60% of the ifosfamide dose, in 3 divided
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Clinical Protocol CA180372
    Page: 1 Protocol Number: CA180372 IND Number: 66,971 Ex-US Non-IND EUDRACT Number 2011-001123-20 Date: 01-Jun-2011 Revised Date: 28-Oct-2013 Clinical Protocol CA180372 A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Revised Protocol Number: 05 Incorporates Amendment 04 Study Director Medical Monitor M. Brigid Bradley-Garelik, MD Co-Principal Investigator Co-Principal Investigator 24-hr Emergency Telephone Number Bristol-Myers Squibb Research and Development Approved v 7.0 930051415 7.0 Clinical Protocol CA180372 BMS-354825 Dasatinib This document is the confidential and proprietary information of Bristol-Myers Squibb Company and its global affiliates (BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it solely for the purpose of assessing whether your organization will participate in and/or the performance of the proposed BMS-sponsored study. Any permitted disclosures will be made only on a confidential "need to know" basis within your organization or to your independent ethics committee(s). Any other use, copying, disclosure or dissemination of this information is strictly prohibited unless expressly authorized in writing by BMS. Any supplemental information (eg, amendments) that may be added to this document is also confidential and proprietary to BMS and must be kept in confidence in the same manner as the contents of this document. Any person who receives this document without due authorization from BMS is requested to return it to BMS or promptly destroy it. All other rights reserved.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: a Scoping Review
    antioxidants Review Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: A Scoping Review Omar Cauli 1,2 1 Frailty and Cognitive Impairment Group (FROG), University of Valencia, 46010 Valencia, Spain; [email protected]; Tel.: +34-96-386-41-82; Fax: +34-96-398-30-35 2 Department of Nursing, University of Valencia, 46010 Valencia, Spain Abstract: Cognitive impairment is one of the most deleterious effects of chemotherapy treatment in cancer patients, and this problem sometimes remains even after chemotherapy ends. Common classes of chemotherapy-based regimens such as anthracyclines, taxanes, and platinum derivatives can induce both oxidative stress in the blood and in the brain, and these effects can be reproduced in neuronal and glia cell cultures. In rodent models, both the acute and repeated administration of doxorubicin or adriamycin (anthracyclines) or cisplatin impairs cognitive functions, as shown by their diminished performance in different learning and memory behavioural tasks. Administration of compounds with strong antioxidant effects such as N-acetylcysteine, gamma-glutamyl cysteine ethyl ester, polydatin, caffeic acid phenethyl ester, and 2-mercaptoethane sulfonate sodium (MESNA) counteract both oxidative stress and cognitive alterations induced by chemotherapeutic drugs. These antioxidant molecules provide the scientific basis to design clinical trials in patients with the aim of reducing the oxidative stress and cognitive alterations, among other probable central nervous system changes, elicited by chemotherapy in cancer patients. In particular, N-acetylcysteine and MESNA are currently used in clinical settings and are therefore attracting scientific attention. Citation: Cauli, O. Oxidative Stress and Cognitive Alterations Induced by Keywords: taxanes; anthracyclines; platinum; cognition; biomarker; N-acetylcysteine; clinical trial Cancer Chemotherapy Drugs: A Scoping Review.
    [Show full text]